We'll get full-blown details right from the horse's mouth in the morning. That's good enough for me.

What I don't know is the sort of detail that we're going to be given in the morning in comparison to what we heard today from Biogen on Aducanumab. 

For example I don't think they mentioned a MoCA score (or the like)  for Aducanumab so that we would be able to compare it to Apabetalone. 

Koo